ID   KNT2_RAT                Reviewed;         430 AA.
AC   P08932; Q5M894;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-2005, sequence version 2.
DT   24-JUL-2024, entry version 162.
DE   RecName: Full=T-kininogen 2;
DE   AltName: Full=Alpha-1-MAP;
DE   AltName: Full=Major acute phase protein;
DE   AltName: Full=T-kininogen II;
DE   AltName: Full=Thiostatin;
DE   Contains:
DE     RecName: Full=T-kininogen 2 heavy chain;
DE     AltName: Full=T-kininogen II heavy chain;
DE   Contains:
DE     RecName: Full=T-kinin;
DE   Contains:
DE     RecName: Full=T-kininogen 2 light chain;
DE     AltName: Full=T-kininogen II light chain;
DE   Flags: Precursor;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 5-430, AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=2413019; DOI=10.1016/s0021-9258(17)38986-x;
RA   Anderson K.P., Heath E.C.;
RT   "The relationship between rat major acute phase protein and the
RT   kininogens.";
RL   J. Biol. Chem. 260:12065-12071(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 238-430.
RX   PubMed=2413018; DOI=10.1016/s0021-9258(17)38984-6;
RA   Furuto-Kato S., Matsumoto A., Kitamura N., Nakanishi S.;
RT   "Primary structures of the mRNAs encoding the rat precursors for bradykinin
RT   and T-kinin. Structural relationship of kininogens with major acute phase
RT   protein and alpha 1-cysteine proteinase inhibitor.";
RL   J. Biol. Chem. 260:12054-12059(1985).
CC   -!- FUNCTION: Kininogens are plasma glycoproteins with a number of
CC       functions: (1) as precursor of the active peptide bradykinin they
CC       effect smooth muscle contraction, induction of hypotension and increase
CC       of vascular permeability. (2) They play a role in blood coagulation by
CC       helping to position optimally prekallikrein and factor XI next to
CC       factor XII. (3) They are inhibitor of thiol proteases.
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space.
CC   -!- TISSUE SPECIFICITY: Plasma.
CC   -!- INDUCTION: In response to an inflammatory stimulant. T-kininogen II
CC       synthesis is induced and the plasma concentration of T-kininogen I is
CC       raised.
CC   -!- PTM: As T-kinin is preceded by a Met instead of an Arg or Lys, it is
CC       not released from its precursor by either tissue or plasma kallikrein.
CC   -!- MISCELLANEOUS: Rats express four types of kininogens: the classical HMW
CC       and LMW kininogens produced by alternative splicing of the same gene,
CC       and two additional LMW-like kininogens: T-I and T-II.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA41570.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC088161; AAH88161.1; -; mRNA.
DR   EMBL; M11661; AAA41570.1; ALT_FRAME; mRNA.
DR   EMBL; M11885; AAA41491.1; -; mRNA.
DR   PIR; B28055; B28055.
DR   RefSeq; NP_001009628.1; NM_001009628.1.
DR   AlphaFoldDB; P08932; -.
DR   SMR; P08932; -.
DR   MEROPS; I25.019; -.
DR   GlyConnect; 604; 6 N-Linked glycans.
DR   GlyGen; P08932; 5 sites, 11 N-linked glycans (1 site).
DR   jPOST; P08932; -.
DR   PaxDb; 10116-ENSRNOP00000055278; -.
DR   Ensembl; ENSRNOT00055007538; ENSRNOP00055005660; ENSRNOG00055004732.
DR   GeneID; 288001; -.
DR   KEGG; rno:288001; -.
DR   UCSC; RGD:1359376; rat.
DR   AGR; RGD:1359376; -.
DR   CTD; 3827; -.
DR   VEuPathDB; HostDB:ENSRNOG00000030387; -.
DR   eggNOG; ENOG502RYAC; Eukaryota.
DR   InParanoid; P08932; -.
DR   OrthoDB; 5223498at2759; -.
DR   PhylomeDB; P08932; -.
DR   TreeFam; TF351852; -.
DR   PRO; PR:P08932; -.
DR   Proteomes; UP000002494; Chromosome 11.
DR   Bgee; ENSRNOG00000030387; Expressed in liver and 16 other cell types or tissues.
DR   ExpressionAtlas; P08932; baseline and differential.
DR   GO; GO:0005576; C:extracellular region; IBA:GO_Central.
DR   GO; GO:0004869; F:cysteine-type endopeptidase inhibitor activity; IBA:GO_Central.
DR   GO; GO:0006953; P:acute-phase response; IEA:UniProtKB-KW.
DR   GO; GO:0030195; P:negative regulation of blood coagulation; IBA:GO_Central.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:0042311; P:vasodilation; IEA:UniProtKB-KW.
DR   CDD; cd00042; CY; 3.
DR   Gene3D; 3.10.450.10; -; 3.
DR   InterPro; IPR000010; Cystatin_dom.
DR   InterPro; IPR046350; Cystatin_sf.
DR   InterPro; IPR027358; Kininogen-type_cystatin_dom.
DR   InterPro; IPR050735; Kininogen_Fetuin_HRG.
DR   InterPro; IPR018073; Prot_inh_cystat_CS.
DR   PANTHER; PTHR13814; FETUIN; 1.
DR   PANTHER; PTHR13814:SF12; KININOGEN-1; 1.
DR   Pfam; PF00031; Cystatin; 3.
DR   SMART; SM00043; CY; 3.
DR   SUPFAM; SSF54403; Cystatin/monellin; 3.
DR   PROSITE; PS00287; CYSTATIN; 2.
DR   PROSITE; PS51647; CYSTATIN_KININOGEN; 3.
PE   1: Evidence at protein level;
KW   Acute phase; Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Protease inhibitor; Pyrrolidone carboxylic acid; Reference proteome;
KW   Repeat; Secreted; Signal; Thiol protease inhibitor; Vasoactive;
KW   Vasodilator.
FT   SIGNAL          1..18
FT   CHAIN           19..430
FT                   /note="T-kininogen 2"
FT                   /id="PRO_0000006703"
FT   CHAIN           19..375
FT                   /note="T-kininogen 2 heavy chain"
FT                   /id="PRO_0000006704"
FT   PEPTIDE         376..386
FT                   /note="T-kinin"
FT                   /id="PRO_0000006705"
FT   CHAIN           387..430
FT                   /note="T-kininogen 2 light chain"
FT                   /id="PRO_0000006706"
FT   DOMAIN          28..131
FT                   /note="Cystatin kininogen-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00979"
FT   DOMAIN          150..253
FT                   /note="Cystatin kininogen-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00979"
FT   DOMAIN          272..375
FT                   /note="Cystatin kininogen-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00979"
FT   REGION          410..430
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         19
FT                   /note="Pyrrolidone carboxylic acid"
FT                   /evidence="ECO:0000250|UniProtKB:P01048"
FT   CARBOHYD        82
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        168
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        204
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        326
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        28..404
FT                   /note="Interchain (between heavy and light chains)"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00979"
FT   DISULFID        83..94
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00979"
FT   DISULFID        107..125
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00979"
FT   DISULFID        141..144
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00979"
FT   DISULFID        205..217
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00979"
FT   DISULFID        228..247
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00979"
FT   DISULFID        263..266
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00979"
FT   DISULFID        327..339
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00979"
FT   DISULFID        350..369
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00979"
FT   CONFLICT        26..27
FT                   /note="MD -> LN (in Ref. 2; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        28
FT                   /note="C -> R (in Ref. 2; AAA41570)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        55
FT                   /note="L -> V (in Ref. 2; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        61
FT                   /note="E -> K (in Ref. 2; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        166
FT                   /note="F -> S (in Ref. 2; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        179
FT                   /note="T -> R (in Ref. 2; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        193
FT                   /note="N -> D (in Ref. 2; AAA41570)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        212
FT                   /note="F -> S (in Ref. 2; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        229
FT                   /note="R -> T (in Ref. 2; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        233
FT                   /note="Y -> H (in Ref. 2; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        415
FT                   /note="A -> L (in Ref. 2; AAA41570)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   430 AA;  47704 MW;  D94628D848C81525 CRC64;
     MKLITILLLC SRLLPSLAQE EGAQEMDCND ETVFQAVDTA LKKYNAELES GNQFLLYRVT
     EGTKKDGAET LYSFKYQIKE GNCSVQSGLT WQDCDFKDAE EAATGECTTT LGKKENKFSV
     ATQICNITPG KGPKKTEEDL CVGCFQPIPM DSSDLKPVLK HAVEHFNNNT KHTHLFALTE
     VKSAHSQVVA GMNYKIIYSI VQTNCSKEDF PFLREDCVPL PYGDHGECRG HTYVDIHNTI
     AGFSQSCDLY PGDDLFSLLP KKCFGCPKNI PVDSPELKEA LGHSIAQLNA QHNHLFYFKI
     DTVKKATSQV VAGTKYVIEF IARETNCSKQ TNTELTADCE TKHLGQSLNC NANVYMRPWE
     NKVVPTVRCQ ALDMMISRPP GFSPFRLVQV QETKEGTTRL LNSCEYKGRL SKAGAGPAPD
     HQAEASTVTP
//
